FindTrial
Sign In

A single-center, prospective, randomized controlled clinical study of nab-paclitaxel combined with oxaliplatin and S-1 (S-1) regimen and docetaxel combined with oxaliplatin and S-1 (s-1) regimen for neoadjuvant treatment of locally advanced gastric cancer

A single-center, prospective, randomized controlled clinical study of nab-paclitaxel combined with oxaliplatin and S-1 (S-1) regimen and docetaxel combined with oxaliplatin and S-1 (s-1) regimen for neoadjuvant treatment of locally advanced gastric cancer

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048252
Enrollment
Unknown
Registered
2021-07-05
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Group 1:Nab-paclitaxel combined with oxaliplatin and S-1
Group 2:Docetaxel in combination with oxaliplatin and S-1

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years; 2. Pre-operative endoscopy confirmed ''adenocarcinoma''; 3. Pre-operative clinical staging over cT3 or cN+; 4. No distant metasteses; 5. ASA score <3.

Exclusion criteria

Exclusion criteria: 1. Multiple primary lesions; 2. ECOG score greater than 2 points.

Design outcomes

Primary

MeasureTime frame
tumor regression grade;—

Countries

China

Contacts

Public ContactZhang Luyang

Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine

zhlytim2014@163.com+86 16621708040

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026